+
Site Tour

TRILUMINATE Pivotal - 2-year update EuroPCR 25, presented by G. Singh

The TRILUMINATE Pivotal trial demonstrated that TriClip™ TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) risk at 2 years, while confirming its exceptional safety and quality of life improvement

Download

LEARN MORE:

EuroPCR Symposium 2025 TriClip

Related Resources

bRIGHT 2-year real-world outcomes

Prognosis of TR after MitraClip for MR

Poster: Primary MR in the Very Elderly

EuroPCR 25 Symposium: MitraClip and TriClip

EuroPCR 2023: Tricuspid valve

T-TEER: Transcatheter Tricuspid Valve Repair - cases, tips, and tricks

TAVI Summit - Cardiac imaging

TAVI Summit - Live case from Berlin

Navitor™: Voice of the Experts Dave Smith

AV VALVES 2023: Trending Topics – Complexity

AV VALVES 2023: Trending Topics – Timing

EuroPCR 2023: COAPT 5-year follow-up

TRENDING TOPICS

CS Webinar-Aortic valvular disease management

TaiIored solutions for lifetime management of aortic valvular heart disease

Prognosis of TR after MitraClip for MR

EXPANDed studies analysis, presented by R. Estevez-Loureiro

Poster: Primary MR in the Very Elderly

Mitral TEER for Primary MR in the very elderly, presented by M. J. Price

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline